Among the 25 patients who met the inclusion criteria, the major response rate was 50% for 6 patients with high TLR3 gene expression (>75th percentile)...High intratumoral TLR3 gene expression was associated with a higher rate of major responses in ccRCC patients treated with immune checkpoint inhibitors (ICIs).